Latest Entries »

HONG KONG, April 23, 2014 /NEWS.GNOM.ES/ — STAR Systems International, an RFID Hardware, Tag and Professional Services provider, today announced that it has appointed Mr. Stephen C. Lockhart as its new Chief Technology Officer.

Stephen Lockhart brings a vast amount of knowledge and experience to STAR Systems. He has over 16 years of experience as a software developer, including 11 years of worldwide experience working with UHF readers, tags and applications. In previous positions with Sirit, Federal Signal Technologies and 3M, Stephen was a key figure in the development of readers, tags and systems, along with the deployment and implementation for RFID projects using ISO 18000 6C / EPC Class 1 Gen 2 in Tolling, Access Control, Logistics and Retail. In his new role as STAR’s CTO, Stephen will lead development and management of new products and systems that STAR will be bringing to the market. Both Application Engineering and Product Management teams will be reporting to him. He also will head STAR’s Professional Services, Solutions & Consulting offerings.

“I am excited to be part of the team at STAR Systems International,” said Stephen Lockhart. “There is a lot of great energy in this fast-growing organization. Our strategy is to do what we do best: focus on the customer and bring innovative and useful RFID products to the market.”

“We are extremely pleased to have Stephen join the STAR Family,” said Bob Karr, Managing Director of STAR Systems International. “His wealth of knowledge and real world experience is unique in the world of passive RFID. Stephen’s leadership as a true industry expert will be key in driving our business and product development as STAR expands throughout the world of RFID.”

Stephen will be based out of the USA in the Dallas, Texas area. In his new role, he will also provide a USA base for STAR Systems International as it expands products’ ad services globally.

About STAR Systems International

STAR Systems International is a member of the STAR RFID & SYSTEMS GROUP. Star Systems International is a Hong Kong-based RFID hardware, tag and services provider, specializing in UHF RFID-enabled vehicle identification and supply chain management applications. Working through an extensive network of value added resellers and systems integrators, STAR Systems provides a wide range of RFID hardware, professional consulting services and technical support. STAR Systems is also affiliated with STAR-RFID, a manufacturer of RFID tags located in Bangkok. For more information on STAR Systems and/or STAR RFID, visit www.star-int.net or www.star-rfid.com.

 

Media Contacts


STAR Systems International:

North American Agency:

Amy Tsang                        

Spectrum Marketing & Communications

Marketing Assistant              

Bob Basmadjian       

Email                              

 Email   

888.457.7755      


 

Read more news from STAR Systems International.

SOURCE STAR Systems International


http://www.star-int.net

MARINA DEL REY, Calif., April 23, 2014 /NEWS.GNOM.ES/ – Join Prostate Oncology Specialists for an educational talk about PROVENGE – a treatment to stimulate the immune system for advanced prostate cancer.  Prostate cancer specialist, Dr. Jeffrey Turner, presents and reviews key topics:

Why PROVENGE might be right for me?
How do I know the PROVENGE treatment is working?
How is PROVENGE different from hormone or chemotherapy?
Does PROVENGE affect my PSA?
How does PROVENGE boost my immune system?

PROVENGE is the first FDA-approved immunotherapy that attacks advanced prostate cancer. PROVENGE is a personalized treatment, a cellular immunotherapy designed to stimulate the patient’s own immune system to identify, target, and remember prostate cancer cells.  Once the patient’s immune cells are collected, they are sent to the PROVENGE manufacturing facility in Seal Beach, CA. There, the patient’s immune cells are combined with PROVENGE, which activates the cells to attack the prostate cancer. PROVENGE reduced the risk of prostate cancer related deaths by 22.5% and can extend survival beyond 2 years.

“The immune system is vital to a person’s survival rate. At Prostate Oncology, we have treated more than100 patients – we use PROVENGE as the backbone of our treatments to make sure the patient’s immune system is as strong as possible to help fight the prostate cancer.” states Dr. Turner.

Prostate Oncology Specialists has conducted clinical trials to evaluate the immune response induced by PROVENGE. For more information on these clinical trials see: http://www.prostateoncology.com/clinical_trials

This educational event is free and open to the public. Hors d’oeuvres will be served. Seating is limited. RSVP by April 28, 2014.

DATE:  

May 7, 2014

TIME

6:30pm – 8:30pm. Doors open at 6:15pm.

TOPIC

“How PROVENGE Can Jumpstart Your Immune System to Attack Your Advanced Prostate Cancer”

SPEAKER

Jeffrey Turner, MD

LOCATION

Old Ranch Country Club – the Sierra Room, 3901 Lampson Avenue, Seal Beach, CA 90740

ABOUT JEFFREY TURNER, MD
Dr. Turner is a board-certified internist and medical oncologist and joined the Prostate Oncology Specialists team with Drs. Mark Scholz and Richard Lam since 2012.  Dr. Turner has specialized in prostate cancer since 2009.  He is a Long Beach and Los Alamitos native, graduated cum laude from USC and he worked in research at UCLA studying infectious disease and molecular biology.  Dr. Turner has published several articles on urologic cancers with an emphasis on prostate cancer.  He is a sub-investigator of a number of ongoing prostate cancer clinical trials.

ABOUT PROVENGE® (sipuleucel-T) is approved by the FDA as an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

PROVENGE is made from your own immune cells. Your cells will be collected at a cell collection center approximately 3 days before each scheduled infusion of PROVENGE. There can be risks associated with the cell collection process, which you should discuss with your doctor before deciding to begin treatment with PROVENGE.

PROVENGE can cause serious reactions. In controlled clinical trials for the treatment of prostate cancer, serious reactions reported in patients in the PROVENGE group included reactions resulting from the infusion of the drug, which occurred within 1 day of infusion, and strokes. Severe infusion reactions included chills, fever, fatigue, weakness, breathing problems (shortness of breath, decreased oxygen level, and wheezing), dizziness, headache, high blood pressure, muscle ache, nausea, and vomiting. Tell your doctor right away if you have breathing problems, chest pains, racing heart or irregular heartbeats, dizziness, nausea, or vomiting after getting PROVENGE because any of these may be signs of heart or lung problems.

The most common side effects reported with PROVENGE were chills, fatigue, fever, back pain, nausea, joint ache, and headache. These are not all the possible side effects of PROVENGE treatment. For more information, talk with your doctor.

Tell your doctor about all your medical problems including heart problems, lung problems or a history of stroke.

Tell your doctor right away if you get a fever over 100°F, or redness at the cell collection or infusion sites, because any of these may be signs of infection.

Tell your doctor about all the medicines you take, including prescription and nonprescription drugs, vitamins, and dietary supplements.

Tell your doctor about any side effect that concerns you or does not go away.

For more information on PROVENGE, please see the Full Prescribing Information or call 1-800-667-5924.

RELATED LINKS
prostateoncology.com
provenge.com

SOURCE Prostate Oncology Specialists, Inc.


http://prostateoncology.com
http://provenge.com

SEATTLE, April 23, 2014 /NEWS.GNOM.ES/ — TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has granted an exclusive license to, the Shanghai Fosun Pharmaceutical Development Co., Ltd., and its subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. (Fosun Pharma), to develop and commercialize the first-ever regimen designed to treat both drug-sensitive TB (DS-TB) and multi-drug resistant TB (MDR-TB) for use within People’s Republic of China, Taiwan, Hong Kong and Macau (Licensed Territory).

PaMZ, a novel TB drug regimen, shows the potential to be a shorter, simpler, safer and affordable treatment for both DS-TB and some forms of MDR-TB. The regimen has reached a major milestone and is now ready to enter a global Phase 3 clinical trial. Shenyang Hongqi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Fosun Pharma, is the largest manufacturer and distributor of TB treatments in China. The collaboration, announced today at the Global Health Product Development Forum, organized by the Bill & Melinda Gates Foundation, in Seattle, Washington, is important to help expedite the final stage of clinical development and, if successful, ensure that the promising PaMZ treatment is made available in the Licensed Territory to the people who need it.

“This collaboration is emblematic of the type of innovative partnerships needed to truly advance global health technologies,” said Mel Spigelman, MD, president and CEO of TB Alliance. “Through this partnership, Fosun Pharma will both help support the global registration of urgently needed new tools for TB, while also retaining the benefits of a traditional product developer within their core market; this is the sort of agreement that product development partnerships are able to achieve to benefit the millions of patients needlessly dying from neglected diseases of poverty such as TB.”

According to a report from the National Health and Family Planning Commission of the People’s Republic of China, the country has the world’s second largest TB epidemic, including MDR-TB, as each year, approximately one million people in the country contract the disease, with 50,000 of those cases estimated to be MDR-TB. New TB treatments are urgently needed. Currently, people with MDR-TB require a minimum of 18 to 24 months of treatment, with thousands of costly pills and daily injections for the first six months of therapy. MDR-TB treatment is cost-prohibitive for many MDR-TB patients and health systems, severely limiting the number of patients who even receive any treatment. 

Under this agreement, Fosun Pharma will support research sites in the People’s Republic of China as part of the newly announced Phase 3 STAND (Shortening TB Treatment by Advancing Novel Drugs) trial and will conduct any additional studies required for regulatory approval of PaMZ in the Licensed Territory. If the regimen is successful, Fosun Pharma will commercialize the PaMZ regimen in the Licensed Territory. As part of the terms of the agreement, the company has committed to the principles of affordability and accessibility for the treatment.  

“TB is a significant issue in our country and there remains a critical need for new and improved tools to overcome the disease,” said Mr. Qiyu Chen, chairman of Fosun Pharma. “We are proud to take a lead role in the fight against TB and contribute to the development of this promising new treatment.”

PaMZ consists of two new drug candidates, PA-824 and moxifloxacin, and pyrazinamide, part of the current first-line treatment. Earlier studies show PaMZ’s potential to treat both DS-TB and MDR-TB patients with the same oral therapy, and to shorten treatment, especially for those with MDR-TB. The development of PaMZ is projected to save years of time by testing new drugs simultaneously as a “drug regimen,” instead of one-by-one. In July 2012, a two-week study published in The Lancet showed that PaMZ appeared to kill patients’ bacteria more quickly than standard therapy after starting treatment.

If successful, the regimen would eliminate the need for injectable drugs and significantly reduce the cost of MDR-TB therapy, in some countries by more than 90 percent, in those patients whose TB organisms are sensitive to the three drugs. It also promises to be compatible with commonly used HIV drugs, helping the millions of people co-infected with TB/HIV.

About TB Alliance (Global Alliance for TB Drug Development)
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from Bill & Melinda Gates Foundation, Department of Foreign Affairs and Trade, Department for International Development (DFID), European Commission (DFAT), Global Health Innovative Technology Fund (GHIT Fund), Irish Aid, National Institute of Allergy and Infectious Disease (NIAID), UNITAID, United States Agency for International Development (USAID) and the United States Food and Drug Administration (FDA). For more information please visit tballiance.org.

About Fosun Pharma
Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) is a leading healthcare company in China, which was listed on Shanghai Stock Exchange in August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited in October 2012 (stock code: 600196-SH, 02196-HK). Specializing in modern biopharmaceutical and healthcare industry, our main businesses include pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services, medical diagnosis and medical devices. With its commitment to innovation for good health, Fosun Pharma aims to become the first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Shenyang Hongqi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Fosun Pharma, has been the largest manufacturer and distributor of TB treatments for over 30 years in China. For more information on Fosun Pharma, please visit
www.fosunpharma.com.

For more information, please contact:
Preeti Singh at +1-(301) 280-5722 or psingh@burnesscommunications.com

SOURCE TB Alliance

SEATTLE, April 23, 2014 /NEWS.GNOM.ES/ — Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase 3 clinical trial.

The announcement by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, accompanied a commitment of significant funding by the Gates Foundation to determine the safety and efficacy of the new drug regimen, which is known as PaMZ. Mr. Gates called on other organizations to support the effort to develop new treatments for TB, a disease that kills an estimated 1.3 million people annually and remains a leading cause of death globally, especially among people who are co-infected with HIV.   

“The results from early phase research suggest that this new drug regimen could provide the breakthrough we need to accelerate progress against this deadly and dangerous disease,” said Mr. Gates. “PaMZ could dramatically reduce the time required to cure drug-resistant TB from two years to just six months, and it could cut the cost of curing drug-resistant TB in low-income countries from thousands of dollars to just a fraction of that cost. Now we need funders to step forward to make next-generation TB drugs like PaMZ a reality.”

Limitations in standard treatment for TB remain a strong barrier to TB control. The treatment and cure of a typical case of drug-sensitive TB currently takes between six and nine months and the drug therapy is long, complicated, and can cause severe side effects. Currently, people with drug-resistant TB require a minimum of 18 to 24 months of treatment. This more extensive therapy requires more than 12,000 pills and daily injections for at least 6 months. The long duration of MDR-TB treatment, combined with the pain and side effects that treatment causes, help to explain why only just over half (53 percent) of patients who currently enter therapy for MDR-TB complete their full course of medicines.

The PaMZ regimen shows promise to significantly shorten therapy, particularly for some forms of MDR-TB. It will be tested in a Phase 3 clinical trial named STAND (Shortening Treatments by Advancing Novel Drugs). If successful, the regimen would eliminate the need for injectable drugs and reduce the cost of MDR-TB therapy in some countries by more than 90 percent in those patients whose TB organisms are sensitive to the three drugs. It also promises to be compatible with commonly used HIV drugs, helping the millions of people co-infected with TB/HIV.

“TB patients, especially those with drug-resistant TB, urgently need cures  that eliminate the need for injectable therapies, require taking fewer pills for a shorter period of time, are less toxic, simpler to administer and cost much less money,” said Dr. Mel Spigelman, president and CEO of TB Alliance, an international non-profit working to develop improved TB treatments. “The STAND trial brings us closer to an era of high-impact drug regimens instead of where we are today, relying on the relics of the mid-20th century.”

The STAND trial will span some 50 study sites across Africa, Asia, Eastern Europe and Latin America. It will test the novel three-drug regimen PaMZ as a shorter, simpler and safer treatment for drug-sensitive and drug-resistant TB. The development of the PaMZ regimen is projected to save years of time by having tested new drugs simultaneously as a “drug regimen” instead of one-by-one.

PaMZ is a three-drug regimen comprised of two candidate drugs that are not yet licensed for use against TB: PA-824 (Pa) and moxifloxacin (M), and one existing antibiotic used in TB treatment today, pyrazinamide (Z). Earlier study results show PaMZ’s potential to treat both drug-sensitive and drug-resistant patients with the same oral therapy, and to dramatically shorten treatment times for some patients. In July 2012, a two-week study published in The Lancet showed that PaMZ appeared to kill the patients’ bacteria more quickly than standard therapy after starting treatment. Findings from a subsequent two-month study are expected to be published later this year.

Support for earlier research of the PaMZ regimen was provided by the Bill & Melinda Gates Foundation (BMGF), the United Kingdom Department for International Development (DFID), the Australia Department for Foreign Affairs (DFAT), US Agency for International Development (USAID), Irish Aid, and the Directorate-General for International Cooperation (DGIS).

While the TB Alliance hopes to launch the STAND trial by the end of this year, Spigelman noted the date will be subject to obtaining adequate funding commitments.

“We thank all our supporters to date, as without their investment, the highly promising PaMZ regimen would not have reached this critical stage,” said Spigelman. “We need new and expanded commitments for the STAND trial, however, if we are to realize the significant potential of this treatment to save millions of lives.”

About the TB Alliance
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from Australia Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, European Commission, Global Health Innovative Technology Fund, Irish Aid, National Institute of Allergy and Infectious Disease, UNITAID, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration. For more information please visit tballiance.org.

For more information, please contact:
Preeti Singh at +1-(301) 280-5722 or
psingh@burnesscommunications.com

SOURCE TB Alliance

– Die STAND-Studie wird die erste Kombinationstherapie erproben, die die Behandlung von medikamentensensitiver und -resistenter Tuberkulose signifikant verkürzen und vereinfachen kann

SEATTLE, 23. April 2014 /NEWS.GNOM.ES/ — Auf Grundlage positiver Ergebnisse früherer klinischer Phasen erreicht die erste Kombinationstherapie, die für die Behandlung medikamentensensitiver und einiger Formen der multiresistenten Tuberkulose (TB) entwickelt wurde, die Phase III der klinischen Prüfung.

Bei der Ankündigung durch Bill Gates, dem Ko-Vorsitzenden der Bill & Melinda Gates Stiftung, wurden signifikante Finanzmittel für die Studie zur Erprobung der Verträglichkeit und der Wirksamkeit der neuen Kombinationstherapie – bekannt als PaMZ – durch die Stiftung zugesagt.

Herr Gates forderte andere Organisationen auf, die Entwicklung neuer Behandlungsmöglichkeiten für Tuberkulose zu unterstützen. Die Krankheit gehört mit geschätzten 1,3 Millionen Opfern jährlich zu den führenden Todesursachen weltweit. Dies gilt insbesondere für Menschen, die mit HIV koinfiziert sind.

“Die Ergebnisse aus frühen Phasen der klinischen Entwicklung deuten darauf hin, dass diese neue Kombinationstherapie den notwendigen Durchbruch für Fortschritte bei der Bekämpfung dieser tödlichen und gefährlichen Krankheit bedeuten könnte,” so Herr Gates. „PaMZ könnte die Behandlungsdauer für medikamentenresistente Tuberkulose deutlich verkürzen – von bisher zwei Jahren auf nur sechs Monate. Zudem könnte es die Behandlungskosten für medikamentenresistente Tuberkulose in Ländern mit geringem Einkommen von Tausenden von Dollar auf einen Bruchteil der bisherigen Kosten reduzieren. Was wir jetzt brauchen, sind Unterstützer und Förderer, um die Tuberkulose-Medikamente der nächsten Generation wie PaMZ, Wirklichkeit werden zu lassen.”

Einschränkungen bei der herkömmlichen Tuberkulose-Behandlung behindern die Tuberkulose-Kontrolle. Die Behandlung und Heilung eines typischen Falles medikamentenresistenter Tuberkulose dauert derzeit zwischen sechs und neun Monaten. Die Behandlung mit Medikamenten ist langwierig, komplex und teilweise mit schwerwiegenden Nebenwirkungen verbunden. Menschen, die von medikamentenresistenter Tuberkulose betroffen sind, müssen sich einer Behandlung von mindestens 18 bis zu 24 Monaten unterziehen. Die aufwendige Therapie erfordert die Einnahme von über 12.000 Tabletten und tägliche Injektionen für mindestens sechs Monate. Die lange Behandlungsdauer von multiresistenter Tuberkulose (MDR-TB), Schmerzen und Nebenwirkungen der Therapie erklären, warum nur etwas mehr als die Hälfte (53%) der Patientinnen und Patienten eine Therapie zu Ende zu führen.

Die PaMZ-Kombinationstherapie verspricht die Tuberkulose-Behandlung deutlich zu verkürzen, insbesondere für einige Formen der multiresistenten Tuberkulose. Die Kombinationstherapie wird nun in einer Phase III-Studie, der sogenannten STAND (Shortening Treatments by Advancing Novel Drugs)-Studie, getestet. Ist die Erprobung erfolgreich, würde die neue Kombinationstherapie die injizierbaren Tuberkulose-Medikamente überflüssig machen. Die Behandlungskosten von multiresistenter Tuberkulose würden sich für Patienten, die auf alle drei enthaltenen Medikamente ansprechen, um bis zu 90 % reduzieren. Darüber hinaus verspricht PaMZ mit Standard-HIV-Medikamenten kombinierbar zu sein, was Millionen von Menschen helfen würde, die mit Tuberkulose und HIV koinfiziert sind.

“Tuberkulose-Patienten, besonders jene mit medikamentenresistenter Tuberkulose, benötigen dringend Therapiemöglichkeiten, die Injektionen überflüssig machen, die die Einnahme von weniger Tabletten über einen kürzeren Zeitraum bedeuten, die weniger toxisch und leichter durchzuführen sind und die weniger kosten”, so Dr. Mel Spigelman, Präsident und Geschäftsführer  der TB Alliance, einer internationalen gemeinnützigen Organisation, die an der Entwicklung verbesserter Tuberkulose-Medikamente arbeitet. „Die STAND-Studie bringt uns einer neuen Ära von hochwirksamen Kombinationstherapien näher. Anders als jetzt, wo wir uns auf Relikte des 20. Jahrhunderts verlassen.”

Die STAND-Studie wird bis zu 50 Studienstandorte in Afrika, Asien, Osteuropa und Lateinamerika umfassen. Die Studie wird die neuartige PaMZ-Kombinationstherapie – bestehend aus drei Medikamenten – als kürzere, vereinfachte und verträglichere Behandlungsmethode für medikamentensensitive und medikamentenresistente Tuberkulose erproben. Die Entwicklung der PaMZ-Kombination wird voraussichtlich jahrelange Forschung ersparen, da mehrere Medikamente im Rahmen eines Therapieschemas gleichzeitig erprobt werden, anstatt jedes Medikament einzeln zu testen.

PaMZ ist ein drei Medikamente umfassendes Therapieschema: zwei der Kandidaten sind noch nicht für die Behandlung von Tuberkulose zugelassen, PA-824 (Pa) und Moxifloxacin (M). Das dritte Medikament ist ein Antibiotikum, das bereits heute für die Tuberkulose-Behandlung eingesetzt wird, Pyrazinamid (Z). Ergebnisse aus früheren Phasen der klinischen Entwicklung haben das Potential von PaMZ gezeigt mit der gleichen oralen Therapie sowohl Patienten mit medikamentensensitiver als auch jene mit medikamentenresistenter Tuberkulose zu behandeln und die Behandlungsdauer für einige Patienten deutlich zu verkürzen. Die Ergebnisse einer zwei-wöchigen Studie, die im Juli 2012 in The Lancet veröffentlicht wurde, haben gezeigt, dass PaMZ die Tuberkulose-Bakterien nach Therapiebeginn schneller abzutöten schien als die Standard-Behandlung. Die Veröffentlichung der Ergebnisse einer Folgestudie mit einer Dauer von zwei Monaten wird für Ende dieses Jahres erwartet.

Unterstützt wurde die bisherige Forschung an der PaMZ-Kombinationstherapie durch die Bill & Melinda Gates Stiftung (BMGF), dem britischen Entwicklungsministerium (DFID), dem Australischen Außenministerium (DFAT), der US-Agentur für Internationale Entwicklung (USAID), Irish Aid und dem Directorate-General for International Cooperation (DGIS).

Zwar hofft die TB Alliance, mit der STAND-Studie bereits Ende dieses Jahres beginnen zu können, allerdings wird dies maßgeblich von einer ausreichenden Finanzierung abhängen, sagte Spigelman.

“Wir danken all jenen, die uns bislang unterstützt haben, denn ohne ihre Investitionen hätte die vielversprechende PaMZ-Kombinationstherapie nicht diese entscheidende Phase erreicht,” sagt Spigelman. „Für die STAND-Studie benötigen wir neue und breitere Unterstützung, wollen wir das signifikante Potential dieser Behandlungsmethode entfalten, um Millionen von Menschenleben zu retten.”

Über die TB Alliance
Die Global Alliance for TB Drug Development (TB Alliance) ist eine gemeinnützige Organisation, die sich der Entwicklung von schneller wirksamen und erschwinglichen Behandlungsmöglichkeiten zur Bekämpfung der Tuberkulose verschrieben hat. Mithilfe innovativer Forschung und mit Partnern auf der ganzen Welt, hat sie das Ziel den gleichberechtigten Zugang zu schnell wirkenden und verbesserten Behandlungsmöglichkeiten sicherzustellen, um einen Beitrag zur globalen Gesundheit und Wohlstand zu leisten. Die TB Alliance arbeitet mit finanzieller Unterstützung des Australischen Außenministeriums, der Bill & Melinda Gates Stiftung, der Europäischen Kommission, dem Global Health Innovative Technology Fund, Irish Aid, dem National Institute of Allergy and Infectious Disease, UNITAID, dem britischen Entwicklungsministerium, der US-Agentur für Internationale Entwicklung und der United States Food and Drug Administration. Weitere Informationen finden Sie unter tballiance.org.

Für weitere Informationen wenden Sie sich bitte an
Preeti Singh unter +1-301-280-5722 oder
psingh@burnesscommunications.com

SOURCE TB Alliance

LONDON, April 23, 2014 /NEWS.GNOM.ES/ — Reportbuyer.com has added a new market research report:

Lens Markets in Europe to 2018 – Market Size, Trends, and Forecasts

http://www.reportbuyer.com/pharma_healthcare/treatments/eye_care/lens_markets_europe_2018_market_size_trends_forecasts_1.html

The industry report package Lens Markets in Europe to 2018 – Market Size, Trends, and Forecasts offers the most up-to-date market data on the actual market situation, trends, and future outlook for lenses in Europe. The package includes lens market country reports from the following countries:

Armenia, Austria, Azerbaijan, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Turkey, Ukraine, United Kingdom

The reports include historic market data from 2007 to 2013 and forecasts until 2018 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key industry data in readily accessible and clearly presented tables and graphs.

The latest market data for this research include:

- Overall lens market size in different European countries, 2007-2018
- Market size of contact lenses in different European countries, 2007-2018
- Market size of spectacle lenses of glass in different European countries, 2007-2018
- Market size of other spectacle lenses in different European countries, 2007-2018
- Growth rates of the overall lens market and different product segments in different European countries, 2007-2018
- Shares of different product segments of the overall lens market in different European countries, 2007, 2013 and 2018
- Market Potential Rates of the overall lens market and different product segments in different European countries

The product segments analyzed in the data reports include:

Contact lenses
Spectacle lenses of glass
Other spectacle lenses

The reports answer the following questions:

- What is the current size of the lens market in different European countries?
- How is the lens market divided into different product segments?
- How are the overall market and different product segments growing?
- How is the market predicted to develop in the future?
- What is the market potential in different countries?

Among the key reasons to purchase include the following:

- Gain an outlook of the historic development, current market situation, trends, and future outlook of the lens market in different European countries to 2018
- Track industry trends and identify market opportunities
- Plan and develop marketing, market-entry, market expansion, and other business strategies by identifying the key market trends and prospects
- Save time and money with the readily accessible key market data included in the report. The market data is clearly presented and can be easily incorporated into presentations, internal reports, etc.

The industry data reports are produced utilizing the standard methodology of Global Research & Data Services by applying, analyzing, and combining a wide range of sources and in-house analysis.
This package includes lens market country reports from the following countries:

Armenia, Austria, Azerbaijan, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Turkey, Ukraine, United Kingdom

Below you can find the table of contents for one of the reports. All the reports have a similar structure and content so that different countries can be easily compared with each other.

Market for Lenses in the Country in Question
Overall Market
Market by Type
Contact lenses
Spectacle lenses of glass
Other spectacle lenses
Forecasts and Future Outlook
Overall Market
Market by Type
Contact lenses
Spectacle lenses of glass
Other spectacle lenses
Market Potential Rates
Lens Market Size Compared to Market Growth in Different Countries
Market Definition
Sources
About Global Research & Data Services

List of Tables

Table 1 Market for lenses in the country in question, 2007-2013 (US dollars)
Table 2 Market for lenses in the country in question, by type, 2007 and 2013 (share)
Table 3 Market for contact lenses in the country in question, 2007-2013 (US dollars)
Table 4 Market for spectacle lenses of glass in the country in question, 2007-2013 (US dollars)
Table 5 Market for other spectacle lenses in the country in question, 2007-2013 (US dollars)
Table 6 Market for lenses in the country in question, 2014-2018 (US dollars)
Table 7 Market for lenses in the country in question, by type, 2007, 2013 and 2018 (share)
Table 8 Market for contact lenses in the country in question, 2014-2018 (US dollars)
Table 9 Market for spectacle lenses of glass in the country in question, 2014-2018 (US dollars)
Table 10 Market for other spectacle lenses in the country in question, 2014-2018 (US dollars)
Table 11 Market Potential Rates of lens industry in the country in question

List of Graphs

Graph 1 Market for lenses in the country in question, 2007-2013 (US dollars)
Graph 2 Market for contact lenses in the country in question, 2007-2013 (US dollars)
Graph 3 Market for spectacle lenses of glass in the country in question, 2007-2013 (US dollars)
Graph 4 Market for other spectacle lenses in the country in question, 2007-2013 (US dollars)
Graph 5 Market for lenses in the country in question, 2007-2018 (US dollars)
Graph 6 Market for contact lenses in the country in question, 2007-2018 (US dollars)
Graph 7 Market for spectacle lenses of glass in the country in question, 2007-2018 (US dollars)
Graph 8 Market for other spectacle lenses in the country in question, 2007-2018 (US dollars)
Graph 9 Lens market size compared to market growth in different countries

Read the full report:
Lens Markets in Europe to 2018 – Market Size, Trends, and Forecasts

http://www.reportbuyer.com/pharma_healthcare/treatments/eye_care/lens_markets_europe_2018_market_size_trends_forecasts_1.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


http://www.reportbuyer.com

Jeremy McGrath Signs Sponsorship with bluemedia for 2014 Lucas Oil Off Road Series (PRNewsFoto/bluemedia)

TEMPE, Ariz., April 23, 2014 /NEWS.GNOM.ES-iReach/ — bluemedia, an industry-leading provider of design, printing and fabrication for use in vehicle, large format and environmental graphic applications, is proud to announce their sponsorship of Jeremy McGrath, seven-time AMA Supercross Champion and Motocross legend, for the 2014 Lucas Oil Off Road Series (LOORS).

(Photo: http://photos.NEWS.GNOM.ES.com/prnh/20140423/77542)

“We couldn’t have chosen a better athlete to sponsor,” said Jared Smith, president of bluemedia. “Jeremy’s Supercross success is unmatched, and his record, 101 career wins and 12 titles, will most likely never be beat. It’s that dedication, talent, and domination of the industry that makes this sponsorship such a great fit. It’s everything bluemedia is known for.”

The sponsorship deal, which includes bluemedia producing all graphics and signage for McGrath’s team’s trucks, haulers, pits, basecamp, hospitality and more, kicked off last month at Wild Horse Pass Motorsports Park in Chandler, AZ, where the Jeremy McGrath Motorsports team battled for supremacy in the highly competitive short course off road racing series. Next up is Lake Elsinore Motorsports Park in California, with the remaining races taking place through the end of October.

“Short course racing is an absolute battle on the track every second of the race,” said McGrath. “It takes a dedicated crew to keep my truck running strong. The team at bluemedia have the same dedication and pride in the team as I do. They keep me and my sponsors looking good on the track and in the pits with the best graphics and signage anywhere!”

Often credited with bringing the sport of Supercross into the mainstream, McGrath is currently pursuing titles on four wheels, racing in the ultra-competitive Pro 2 class, where he frequently places in the Top Ten of any given event. His other sponsors include Loctite, Fuel Off-Road, Maxxis, iON Camera, 3M and more.

For more information on the Jeremy McGrath Motorsports team, or for a schedule of Pro 2 races, please visit http://www.jeremymcgrath3.com/.
 

About bluemedia®

bluemedia is a national provider of large-format printing and structural signage solutions. From design to install, our entire team is dedicated to transforming the marketing industry through innovative solutions and our commitment to “Make it Perfect.” That’s our passion, and we mean it. We know that if we consistently deliver superior products and outstanding service, you’ll always come back for more. That’s why you can completely rely on our state-of-the-art technology and 120,000-square-foot production facility, as well as our professional, detail-oriented staff and award-winning design team. Browse our products and services online anytime at bluemedia.com.

Media Contact: Joe Holt, bluemedia, 480-317-1333, joe.holt@bluemedia.com

News distributed by PR Newswire iReach: https://ireach.NEWS.GNOM.ES.com

SOURCE bluemedia


http://www.bluemedia.com

AKRON, Ohio, April 23, 2014 /NEWS.GNOM.ES/ – Stow-based Vallmar Company has teamed up with Weaver Pro-Pak of Cuyahoga Falls, Ohio for the finishing, assembling and packaging of The Golden Rule MarbleT. Weaver Industries is a non-profit organization providing individuals with disabilities vocational training and employment opportunities. Founded in 1971 as a 501(C)3 non-profit organization, The Weaver name stems from Carlene Weaver who was a strong advocate for individuals with disabilities. She was instrumental in improving the lives of many individuals with disabilities in Summit County by advocating for meaningful vocational opportunities.

The patented and trademarked, The Golden Rule MarbleT is manufactured by the Vallmar Company of Stow, Ohio. Owned by the Iliev family, Vall, Pepa and Martin Iliev, Vallmar has a company philosophy of treating others as they wish to be treated and they hope to help spread this message of kindness to all around the world with the Golden Rule MarbleT. Pepa Iliev, Co-Founder of Vallmar Company, said: “We succeed only when we provide our clients a top quality golden rule marble product, designed to inspire reciprocity and kindness in all who encounter it.”

Applying The Golden Rule to daily interactions with people is a key to success and to healthy relationships. As such, the teaming of two companies that operate daily on Golden Rule principles makes a perfect combination!

The Golden Rule MarbleT is a unique, pocket-sized keepsake, consisting of the team-building message of “The Golden Rule” inscribed on a brass ring wrapped around an acrylic marble. Translucent colors give the appearance of “light coming from within.” Foster team work and Build Relationships with this unique promotional idea!

Each one-inch marble comes with a double-sided pamphlet imprinted with the golden rule – neatly folded into a clear, acrylic presentation box. The pamphlet can be custom printed with a special message, statement of values, or other unique affirmation.
The Golden Rule MarbleT is available in six high-quality, tiger-eye acrylic colors (white, black, green, blue, red and translucent blue). It has a brass ring upon which is hand-inscribed “Do unto others as you would have them do unto you.”

To purchase Golden Rule Marbles, call +1.330.686.2472 or visit www.Golden-Rule-Marble.com. A single marble gift set retails $19.95 with volume discounts available for higher quantities. If you’re looking for a way to encourage strong moral standards within your organization and promote those same standards to your clients, vendors and partners, call or visit online now.

About Vallmar Company and Vallmar Studio
A wholly-owned subsidiary of Vallmar Company, Vallmar Studio offers inventors the resources they need to give their inventions a fair chance in the competitive marketplace. From prototypes to product management, engineering to licensing support, Vallmar Studio helps inventors manage the process from start to finish. Vallmar Studio is currently accepting inquiries from qualified outside Sales Representatives. New product sales, business-to-business (b2b) and business-to-consumer (b2c) experience required. Competitive commissions paid for performance. For more information about Vallmar, visit http://www.vallmar.com or call 800-986-0795.


Press Release Contact Information:
Pepa Iliev
V.P. of Operations
Vallmar Company
(330) 686-2472
GoldenRule@vallmar.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.
http://www.webwire.com/ViewPressRel.asp?aId=187117

SOURCE Vallmar Company


http://www.vallmar.com

MELVILLE, N.Y., April 23, 2014 /NEWS.GNOM.ES/ – P&F Industries Inc. (NASDAQ GM: PFIN) is correcting the date stated in its press release issued earlier today that it plans to release its results for the three-month period March 31, 2014, as well as hold a scheduled conference call at 11:00 (Eastern Time), to Tuesday, May 13, 2014. 

The corrected press release follows:

MELVILLE, N.Y. April 23, 2014 – P&F Industries, Inc. (NASDAQ GM: PFIN), plans to release its results for the three-month period March 31, 2014 before the market opens on Tuesday, May 13, 2014.  The company has scheduled a conference call beginning at 11:00 a.m. Eastern time the same day.

You may join this conference call by dialing 866-548-2693, or you may wish to listen only via a live web cast accessible at www.800rollcall.com/webpresenter/.  We urge you to register at the site at least 15 minutes prior to the call by entering a participant code 8741394. For those who cannot listen to the live broadcast, a replay of the call will be accessible through the Company’s web site beginning approximately twenty-four to forty-eight hours later.

About P&F Industries Inc.

P&F Industries, Inc., through its two wholly-owned operating subsidiaries, Continental Tool Group, Inc. and Countrywide Hardware, Inc., manufactures and/or imports air-powered tools sold principally to the retail, industrial, and automotive markets, and various residential hardware such as fencing hardware, as well as door and window hardware. P&F’s products are sold under their own trademarks, as well as under the private labels of major manufacturers and retailers.

SOURCE P&F Industries, Inc.


http://www.pfina.com

LONDON, April 23, 2014 /NEWS.GNOM.ES/ — Reportbuyer.com has added a new market research report:

Spectacle Frame and Mounting Markets in Americas to 2018 – Market Size, Trends, and Forecasts

http://www.reportbuyer.com/pharma_healthcare/treatments/eye_care/spectacle_frame_mounting_markets_americas_2018_market_size_trends_forecasts_1.html

This industry report package offers the most up-to-date market data on the actual market situation, trends, and future outlook for spectacle frames and mountings in different American countries. The package includes spectacle frame and mounting country reports from the following countries:

Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, United States

The reports include historic market data from 2007 to 2013 and forecasts until 2018 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key industry data in readily accessible and clearly presented tables and graphs.

The latest market data for this research include:

- Overall spectacle frame and mounting market size, 2007-2018
- Spectacle frame and mounting market size by product segment, 2007-2018
- Growth rates of the overall spectacle frame and mounting market and different product segments, 2007-2018
- Shares of different product segments of the overall spectacle frame and mounting market, 2007, 2013 and 2018
- Market Potential Rates of the overall spectacle frame and mounting market and different product segments

The product segments analyzed in the data reports include:

Spectacle frames and mountings of plastic
Other spectacle frames and mountings
Parts of spectacle frames and mountings

The reports answer the following questions:

- What is the current size of the spectacle frame and mounting market in different American countries?
- How is the spectacle frame and mounting market divided into different product segments?
- How are the overall market and different product segments growing?
- How is the market predicted to develop in the future?
- What is the market potential compared to other countries?

Among the key reasons to purchase include the following:

- Gain an outlook of the historic development, current market situation, trends, and future outlook of the spectacle frame and mounting market in different American countries to 2018
- Track industry trends and identify market opportunities
- Plan and develop marketing, market-entry, market expansion, and other business strategies by identifying the key market trends and prospects
- Save time and money with the readily accessible key market data included in the report. The market data is clearly presented and can be easily incorporated into presentations, internal reports, etc.

The industry data reports are produced utilizing the standard methodology of Global Research & Data Services by applying, analyzing, and combining a wide range of sources and in-house analysis.
This market research report package includes country reports from the following countries:

Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, United States

Below you can find the table of contents for one of the reports. All the reports have a similar structure and content so that different countries can be easily compared with each other.

Market for Spectacle Frames and Mountings in the Country in Question
Overall Market
Market by Type
Spectacle frames and mountings of plastic
Other spectacle frames and mountings
Parts of spectacle frames and mountings
Forecasts and Future Outlook
Overall Market
Market by Type
Spectacle frames and mountings of plastic
Other spectacle frames and mountings
Parts of spectacle frames and mountings
Market Potential Rates
Spectacle Frame and Mounting Market Size Compared to Market Growth in Different Countries
Market Definition
Sources
About Global Research & Data Services

List of Tables

Table 1 Market for spectacle frames and mountings in the country in question, 2007-2013 (US dollars)
Table 2 Market for spectacle frames and mountings in the country in question, by type, 2007 and 2013 (share)
Table 3 Market for spectacle frames and mountings of plastic in the country in question, 2007-2013 (US dollars)
Table 4 Market for other spectacle frames and mountings in the country in question, 2007-2013 (US dollars)
Table 5 Market for parts of spectacle frames and mountings in the country in question, 2007-2013 (US dollars)
Table 6 Market for spectacle frames and mountings in the country in question, 2014-2018 (US dollars)
Table 7 Market for spectacle frames and mountings in the country in question, by type, 2007, 2013 and 2018 (share)
Table 8 Market for spectacle frames and mountings of plastic in the country in question, 2014-2018 (US dollars)
Table 9 Market for other spectacle frames and mountings in the country in question, 2014-2018 (US dollars)
Table 10 Market for parts of spectacle frames and mountings in the country in question, 2014-2018 (US dollars)
Table 11 Market Potential Rates of spectacle frame and mounting industry in the country in question

List of Graphs

Graph 1 Market for spectacle frames and mountings in the country in question, 2007-2013 (US dollars)
Graph 2 Market for spectacle frames and mountings of plastic in the country in question, 2007-2013 (US dollars)
Graph 3 Market for other spectacle frames and mountings in the country in question, 2007-2013 (US dollars)
Graph 4 Market for parts of spectacle frames and mountings in the country in question, 2007-2013 (US dollars)
Graph 5 Market for spectacle frames and mountings in the country in question, 2007-2018 (US dollars)
Graph 6 Market for spectacle frames and mountings of plastic in the country in question, 2007-2018 (US dollars)
Graph 7 Market for other spectacle frames and mountings in the country in question, 2007-2018 (US dollars)
Graph 8 Market for parts of spectacle frames and mountings in the country in question, 2007-2018 (US dollars)
Graph 9 Spectacle frame and mounting market size compared to market growth in different countries

Read the full report:
Spectacle Frame and Mounting Markets in Americas to 2018 – Market Size, Trends, and Forecasts

http://www.reportbuyer.com/pharma_healthcare/treatments/eye_care/spectacle_frame_mounting_markets_americas_2018_market_size_trends_forecasts_1.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


http://www.reportbuyer.com

Powered by WordPress and Motion by 85ideas.